CORCEPT THERAPEUTICS INC — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Corcept reported Q3 2026 revenue of $340.5M (64% YoY growth), with Korlym/generic at $249.1M and Lifyorli at $91.4M (launched April 1, 2026; 92% sequential growth; 2,300+ patients, 1,700+ prescribers). Net income was $126.8M vs. $19.7M in Q3 2025. Cash increased to $662.3M. The company reaffirmed 2026 guidance of $1.1–$1.2B revenue. BELLA Part A ovarian cancer trial showed median PFS 7.2 months, ORR 59%, 6-month OS 88%; stronger in treatment-naive patients (PFS 8.1, ORR 66%, OS 91%). Relacorilant resubmitted to FDA (PDUFA date December 17, 2026); European MAA recommendation for platinum-resistant ovarian cancer expected approval by year-end.
Why this rating
Strong Q3 growth and Lifyorli traction (>$90M annualized run-rate in new product; ~1.5% of market cap). Positive clinical data supports label expansion. Near-term FDA decision on relacorilant and EU approval material but not transformational relative to $6.1B market cap and established revenue base.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.